Vaš brskalnik ne omogoča JavaScript!
JavaScript je nujen za pravilno delovanje teh spletnih strani. Omogočite JavaScript ali pa uporabite sodobnejši brskalnik.
Nacionalni portal odprte znanosti
Odprta znanost
DiKUL
slv
|
eng
Iskanje
Brskanje
Novo v RUL
Kaj je RUL
V številkah
Pomoč
Prijava
Nicotinic acetylcholine receptors in cancer : limitations and prospects
ID
Bele, Tanja
(
Avtor
),
ID
Turk, Tom
(
Avtor
),
ID
Križaj, Igor
(
Avtor
)
PDF - Predstavitvena datoteka,
prenos
(6,42 MB)
MD5: 8F0B4290B31208E76FFC026222F5B67F
URL - Izvorni URL, za dostop obiščite
https://www.sciencedirect.com/science/article/pii/S0925443923002417
Galerija slik
Izvleček
Nicotinic acetylcholine receptors (nAChRs) have long been considered to solely mediate neurotransmission. However, their widespread distribution in the human body suggests a more diverse physiological role. Additionally, the expression of nAChRs is increased in certain cancers, such as lung cancer, and has been associated with cell proliferation, epithelial-to-mesenchymal cell transition, angiogenesis and apoptosis prevention. Several compounds that interact with these receptors have been identified as potential therapeutic agents. They have been tested as drugs for treating nicotine addiction, alcoholism, depression, pain and Alzheimer's disease. This review focuses on nAChR-mediated signalling in cancer, presenting opportunities for the development of innovative nAChR-based anticancer drugs. It displays the differences in expression of each nAChR subunit between normal and cancer cells for selected cancer types, highlighting their possible involvement in specific cases. Antagonists of nAChRs that could complement existing cancer therapies are summarised and critically discussed. We hope that this review will stimulate further research on the role of nAChRs in cancer potentially leading to innovative cancer therapies.
Jezik:
Angleški jezik
Ključne besede:
nAChR
,
cancer
,
signalling
,
antagonist
,
apoptosis
,
angiogenesis
,
mitochondria
,
therapy
Vrsta gradiva:
Članek v reviji
Tipologija:
1.02 - Pregledni znanstveni članek
Organizacija:
MF - Medicinska fakulteta
BF - Biotehniška fakulteta
Status publikacije:
Objavljeno
Različica publikacije:
Objavljena publikacija
Leto izida:
2024
Št. strani:
18 str.
Številčenje:
Vol. 1870, iss. 1, art. 166875
PID:
20.500.12556/RUL-152834
UDK:
577.2
ISSN pri članku:
0925-4439
DOI:
10.1016/j.bbadis.2023.166875
COBISS.SI-ID:
164011779
Datum objave v RUL:
08.12.2023
Število ogledov:
387
Število prenosov:
42
Metapodatki:
Citiraj gradivo
Navadno besedilo
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Kopiraj citat
Objavi na:
Gradivo je del revije
Naslov:
Biochimica et biophysica acta. Molecular basis of disease
Skrajšan naslov:
Biochim. biophys. acta, Mol. basis dis.
Založnik:
Elsevier
ISSN:
0925-4439
COBISS.SI-ID:
14635559
Licence
Licenca:
CC BY-NC-ND 4.0, Creative Commons Priznanje avtorstva-Nekomercialno-Brez predelav 4.0 Mednarodna
Povezava:
http://creativecommons.org/licenses/by-nc-nd/4.0/deed.sl
Opis:
Najbolj omejujoča licenca Creative Commons. Uporabniki lahko prenesejo in delijo delo v nekomercialne namene in ga ne smejo uporabiti za nobene druge namene.
Projekti
Financer:
ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:
P1-0207
Naslov:
Toksini in biomembrane
Financer:
ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Program financ.:
Young researchers
Številka projekta:
1000-19-0106
Podobna dela
Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:
Nazaj